• Earlier in April 2026, Baxter International showcased new additions to its Global Surgical Solutions and Patient Support Systems portfolios at the AORN Global Surgical Conference, including the AAT XR spine surgical table and Dynamo Series smart stretcher, while also highlighting its Advanced Surgery hemostatic and sealing agents.
• The combination of workflow-focused surgical equipment and connected patient support solutions underlines Baxter’s emphasis on easing staff strain and improving operating room efficiency for healthcare providers.
• We’ll now examine how easing logistics and energy costs following the Strait of Hormuz reopening could influence Baxter’s investment narrative.

Invest in the nuclear renaissance through our list of 93 elite nuclear energy infrastructure plays powering the global AI revolution.

Baxter International Investment Narrative Recap

To own Baxter, you need to believe that its push into smarter surgical and patient support technologies can eventually translate into healthier margins, even as the company works through losses and operational growing pains. The Strait of Hormuz reopening, with its potential to ease logistics and energy costs, supports that margin story at the margin, but does not remove nearer term risks around fluid usage, product pauses, and ongoing cost reduction efforts.

Among recent announcements, the AAT XR spine surgical table and Dynamo Series smart stretcher stand out as directly relevant to Baxter’s emphasis on workflow efficiency and connected care. If hospitals continue adopting equipment that saves staff time and improves patient handling, these offerings could support Baxter’s innovation led catalyst, while also providing some counterweight to margin compression and demand uncertainty across more traditional hospital products.

Yet even as logistics pressures ease, investors should be aware that execution risks around product quality, hospital demand patterns, and margin recovery remain...

Baxter International's narrative projects $12.1 billion revenue and $913.6 million earnings by 2028. This requires 3.7% yearly revenue growth and a $1,160.6 million earnings increase from $-247.0 million today.

Uncover how Baxter International's forecasts yield a $21.63 fair value, a 15% upside to its current price.

Exploring Other Perspectives

The more cautious analysts paint a different picture, assuming revenue of about US$11.9 billion and earnings of roughly US$753 million by 2029, reminding you that views on Baxter’s margin and execution risks can vary widely and may shift again as the latest logistics and product news is absorbed.

Explore 6 other fair value estimates on Baxter International - why the stock might be worth 21% less than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Baxter International research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Baxter International research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Baxter International's overall financial health at a glance.

Searching For A Fresh Perspective?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• This technology could replace computers: discover 25 stocks that are working to make quantum computing a reality.
• AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.